Reported Tuberculosis in the United States, 2020

Return to Main Menu

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20181

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2017
Reporting Area Total Cases with Therapy Extended2,3 Reasons Therapy was Extended
Rifampin Resistance Adverse Event Nonadherence Treatment Failure Clinically Indicated Other
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
United States 788 66 (8.4) 120 (15.2) 97 (12.3) 6 (0.8) 294 (37.3) 292 (37.1)
Alabama 9 1 (11.1) 1 (11.1) 2 (22.2) 0 (0.0) 1 (11.1) 4 (44.4)
Alaska 5 0 (0.0) 0 (0.0) 2 (40.0) 0 (0.0) 3 (60.0) 0 (0.0)
Arizona 19 4 (21.1) 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) 5 (26.3)
Arkansas 10 0 (0.0) 1 (10.0) 8 (80.0) 0 (0.0) 1 (10.0) 0 (0.0)
California 220 16 (7.3) 62 (28.2) 32 (14.5) 2 (0.9) 84 (38.2) 64 (29.1)
Colorado 4 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 2 (50.0) 1 (25.0)
Connecticut 3 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0)
Delaware 2 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 1 (50.0)
District of Columbia 0 0 0 0 0 0 0
Florida 21 1 (4.8) 2 (9.5) 1 (4.8) 1 (4.8) 17 (81.0) 2 (9.5)
Georgia 21 2 (9.5) 0 (0.0) 3 (14.3) 0 (0.0) 4 (19.0) 18 (85.7)
Hawaii 7 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (85.7)
Idaho 1 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Illinois 26 0 (0.0) 5 (19.2) 3 (11.5) 0 (0.0) 11 (42.3) 10 (38.5)
Indiana 8 2 (25.0) 0 (0.0) 0 (0.0) 1 (12.5) 3 (37.5) 2 (25.0)
Iowa 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (50.0) 2 (50.0)
Kansas 0 0 0 0 0 0 0
Kentucky 5 0 (0.0) 1 (20.0) 2 (40.0) 0 (0.0) 2 (40.0) 4 (80.0)
Louisiana 16 0 (0.0) 2 (12.5) 0 (0.0) 0 (0.0) 7 (43.8) 7 (43.8)
Maine 0 0 0 0 0 0 0
Maryland 31 1 (3.2) 2 (6.5) 2 (6.5) 0 (0.0) 11 (35.5) 18 (58.1)
Massachusetts 28 1 (3.6) 2 (7.1) 1 (3.6) 0 (0.0) 8 (28.6) 16 (57.1)
Michigan 5 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (80.0)
Minnesota 23 7 (30.4) 2 (8.7) 3 (13.0) 0 (0.0) 11 (47.8) 1 (4.3)
Mississippi 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 3 (75.0)
Missouri 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (100.0)
Montana 0 0 0 0 0 0 0
Nebraska 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
Nevada 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
New Hampshire 0 0 0 0 0 0 0
New Jersey 29 4 (13.8) 0 (0.0) 3 (10.3) 0 (0.0) 14 (48.3) 9 (31.0)
New Mexico 3 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3) 2 (66.7)
New York State4 15 3 (20.0) 0 (0.0) 2 (13.3) 0 (0.0) 5 (33.3) 10 (66.7)
New York City 28 3 (10.7) 5 (17.9) 4 (14.3) 1 (3.6) 3 (10.7) 12 (42.9)
North Carolina 13 0 (0.0) 2 (15.4) 3 (23.1) 0 (0.0) 5 (38.5) 4 (30.8)
North Dakota 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
Ohio 16 2 (12.5) 1 (6.3) 0 (0.0) 0 (0.0) 7 (43.8) 7 (43.8)
Oklahoma 5 3 (60.0) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Oregon 8 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 7 (87.5) 0 (0.0)
Pennsylvania 28 1 (3.6) 5 (17.9) 3 (10.7) 1 (3.6) 15 (53.6) 3 (10.7)
Rhode Island 5 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0) 2 (40.0)
South Carolina 6 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 5 (83.3)
South Dakota 1 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tennessee 7 0 (0.0) 1 (14.3) 1 (14.3) 0 (0.0) 3 (42.9) 2 (28.6)
Texas 112 6 (5.4) 9 (8.0) 11 (9.8) 0 (0.0) 48 (42.9) 47 (42.0)
Utah 3 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3) 2 (66.7)
Vermont 0 0 0 0 0 0 0
Virginia 12 1 (8.3) 1 (8.3) 0 (0.0) 0 (0.0) 6 (50.0) 5 (41.7)
Washington 10 0 (0.0) 3 (30.0) 1 (10.0) 0 (0.0) 1 (10.0) 6 (60.0)
West Virginia 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0)
Wisconsin 6 0 (0.0) 2 (33.3) 1 (16.7) 0 (0.0) 2 (33.3) 1 (16.7)
Wyoming 0 0 0 0 0 0 0
American Samoa5 0 0 0 0 0 0 0
Fed. States of Micronesia5 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0)
Guam5 3 0 (0.0) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0)
Marshall Islands5 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Northern Mariana Islands5 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Puerto Rico5 4 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 2 (50.0) 2 (50.0)
Palau5 0 0 0 0 0 0 0
U.S. Virgin Islands5 0 0 0 0 0 0 0

1Most recent year for which data are available.
2Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.
3Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).
4Excludes New York City.
5Not included in U.S. totals.

Note: Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.